West Pharmaceutical Services, Inc. (WST) Stock Analysis
West Pharmaceutical Services combines a regulatory-embedded moat with biologics and GLP-1 growth, but its 42.0x trailing P/E leaves execution and valuation risk for investors.
Overview
**West Pharmaceutical Services is a regulatory-embedded supplier to injectable biopharmaceuticals, with Proprietary Products generating 83% of sales and West Vantage contributing 17%.** Its NovaPure, Westar, Envision, SelfDose, and Crystal Zenith products are specified in drug filings, creating high switching costs and recurring demand across multi-decade therapy lifecycles. Biologics represent 43% of sales and GLP-1 elastomers 10%, while the company wins more than 90% of new biologics launches. Q2 2026 revenue rose 13.8% to $872.3 million, adjusted EPS increased 28.8% to $2.37, and adjusted operating margin expanded 230 basis points to 22.6%. Management raised fiscal 2026 organic sales growth guidance to 10.0%–11.0% and adjusted EPS guidance to $8.85–$9.05. At $328.20 on July 24, 2026, the stock trades at 42.0x trailing earnings, 35.4x forward earnings, and 7.09x sales, so valuation is demanding. **The principal near-term catalysts are Annex 1 conversions, GLP-1 growth, Dublin capacity, and West Vantage recovery after the cyber incident.** Sell-side targets range from $410.00 to $447.00.